{"id":390317,"date":"2019-12-06T00:00:00","date_gmt":"2019-12-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0010-2019-biopharma-diabetic-nephropathy-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-03-31T10:45:59","modified_gmt":"2026-03-31T10:45:59","slug":"dlsfmd0010-2019-biopharma-diabetic-nephropathy-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0010-2019-biopharma-diabetic-nephropathy-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Diabetic Nephropathy | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>Diabetic nephropathy (<abbr title=\"diabetic nephropathy\">DN<\/abbr>), also referred to as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to halt the frequent progression of\u00a0<abbr title=\"diabetic nephropathy\">DN<\/abbr>\u00a0to kidney disease and, ultimately, kidney failure\u2014a condition associated with severe morbidity \/ mortality and high costs to patients, payers, and healthcare systems. As a result, key opinion leaders indicate that efficacious therapies for\u00a0<abbr title=\"diabetic nephropathy\">DN<\/abbr>\u00a0are a major unmet need, and they weigh in on the anticipated nephroprotective effects that endothelin receptor antagonists, mineralocorticoid receptor antagonists, and\u00a0<abbr title=\"sodium glucose cotransporter\">SGLT<\/abbr>-2 inhibitor may offer. These therapies represent the first potentially disease-modifying therapies, should they prove efficacious and safe. The increasing prevalence of\u00a0<abbr title=\"diabetic nephropathy\">DN<\/abbr>, exacerbated by the dynamics between clinicians seeking to prescribe new, premium-priced therapies and payers seeking to control costs among an already expensive population, will help shape the changing\u00a0<abbr title=\"diabetic nephropathy\">DN<\/abbr>\u00a0market over the next ten years.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>Will the inclusion of cardiovascular endpoints in the clinical trials for select therapies be a competitive advantage once commercially available?<\/li>\n<li>How do\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s view the different mechanisms of action of the different therapies in early- and late-phase clinical development?<\/li>\n<li>What are the greatest remaining unmet needs in\u00a0<abbr title=\"diabetic nephropathy\">DN<\/abbr>? Which drugs in development will fulfill these unmet needs?<\/li>\n<li>What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?<\/li>\n<\/ul>\n<p><em>Disease Landscape &#038; Forecast:\u00a0<\/em>Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390317","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-nephropathy","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390317\/revisions"}],"predecessor-version":[{"id":576571,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390317\/revisions\/576571"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}